NEWS
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
Carisma Therapeutics (Nasdaq: CARM) has announced the nomination of the first in vivo CAR-M development candidate, targeting Glypican-3 (GPC3), under its collaboration with Moderna. This candidate is designed to treat solid tumors, including hepatocellular carcinoma (HCC), the fastest-rising cause of cancer-related death in the U.S.
This nomination triggers a $2 million milestone payment to Carisma and leverages Carisma's expertise in engineering CAR-M with Moderna's mRNA and lipid nanoparticle platform. Pre-clinical data show the candidate can create CAR-M directly in vivo, redirecting myeloid cells to attack cancer cells.
The program advances under the 2022 strategic collaboration agreement between Carisma and Moderna, aiming to discover and commercialize in vivo CAR-M therapeutics. Moderna has also nominated four additional undisclosed oncology research targets under this collaboration.
This nomination triggers a $2 million milestone payment to Carisma and leverages Carisma's expertise in engineering CAR-M with Moderna's mRNA and lipid nanoparticle platform. Pre-clinical data show the candidate can create CAR-M directly in vivo, redirecting myeloid cells to attack cancer cells.
The program advances under the 2022 strategic collaboration agreement between Carisma and Moderna, aiming to discover and commercialize in vivo CAR-M therapeutics. Moderna has also nominated four additional undisclosed oncology research targets under this collaboration.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1259Followers
76Following
8847Visitors
Follow